{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:38:21Z","timestamp":1790386701727,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clbc.2016.12.004","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T04:19:59Z","timestamp":1482553199000},"page":"195-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Relationship Between Tamoxifen-associated Nonalcoholic Fatty Liver Disease and the Prognosis of Patients With Early-stage Breast Cancer"],"prefix":"10.1016","volume":"17","author":[{"given":"Meiying","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijia","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2016.12.004_bib1","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1021\/ja508185d","article-title":"Mechanism of the third oxidative step in the conversion of androgens to estrogens by cytochrome P450 19A1 steroid aromatase","volume":"136","author":"Yoshimoto","year":"2014","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.clbc.2016.12.004_bib2","first-page":"688","article-title":"The natural history of hormone receptor-positive breast cancer","volume":"26","author":"Lim","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.clbc.2016.12.004_bib3","doi-asserted-by":"crossref","first-page":"e98805","DOI":"10.1371\/journal.pone.0098805","article-title":"Combination treatment of tamoxifen with risperidone in breast cancer","volume":"9","author":"Yeh","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2016.12.004_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0031-6997(24)01358-9","article-title":"Basic guide to the mechanisms of antiestrogen action","volume":"50","author":"MacGregor","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clbc.2016.12.004_bib5","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1200\/JCO.2007.12.2747","article-title":"Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype","volume":"25","author":"Rakha","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2016.12.004_bib6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4048\/jbc.2012.15.3.288","article-title":"Survival benefit of tamoxifen in estrogenreceptor-negative and progesterone receptor-positive low grade breast cancer patients","volume":"15","author":"Yang","year":"2012","journal-title":"J\u00a0Breast Cancer"},{"key":"10.1016\/j.clbc.2016.12.004_bib7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2016.12.004_bib8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7326\/0003-4819-123-3-199508010-00018","article-title":"Tamoxifen-induced steatohepatitis","volume":"123","author":"Pratt","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clbc.2016.12.004_bib9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clbc.2016.12.004_bib10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/hep.23813","article-title":"Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis","volume":"52","author":"Cole","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.clbc.2016.12.004_bib11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/bmj.38391.663287.E0","article-title":"Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial","volume":"330","author":"Bruno","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2016.12.004_bib12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.toxlet.2010.10.008","article-title":"Gene expression profiling of murine hepatic steatosis induced by tamoxifen","volume":"199","author":"Lee","year":"2010","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.clbc.2016.12.004_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/carcin\/bgu247","article-title":"Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer","volume":"36","author":"Liu","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.clbc.2016.12.004_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-005-6654-9","article-title":"Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study","volume":"94","author":"Bahl","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2016.12.004_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF01806329","article-title":"Body size and breast cancer prognosis: a critical review of the evidence","volume":"16","author":"Goodwin","year":"1990","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2016.12.004_bib16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2002.20.4.1128","article-title":"Weight loss in breast cancer patient management","volume":"20","author":"Chlebowski","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2016.12.004_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.clbc.2016.12.004_bib18","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1053\/gast.2002.36572","article-title":"AGA technical review on nonalcoholic fatty liver disease","volume":"123","author":"Sanyal","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clbc.2016.12.004_bib19","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2016.12.004_bib20","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.2010.32.2933","article-title":"Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer","volume":"29","author":"Hackshaw","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2016.12.004_bib21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2016.12.004_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2214\/ajr.180.1.1800129","article-title":"Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy","volume":"180","author":"Nishino","year":"2003","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.clbc.2016.12.004_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/sj.ijo.0801488","article-title":"Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer","volume":"25","author":"Nguyen","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.clbc.2016.12.004_bib24","doi-asserted-by":"crossref","first-page":"e1718","DOI":"10.1097\/MD.0000000000001718","article-title":"Selective estrogen receptor modulator-associated nonalcoholic fatty liver disease improved survival in patients with breast cancer: a retrospective cohort analysis","volume":"94","author":"Zheng","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clbc.2016.12.004_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14740338.6.1.1","article-title":"Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?","volume":"6","author":"Osman","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clbc.2016.12.004_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10549-005-9104-9","article-title":"Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist","volume":"97","author":"Ahmed","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2016.12.004_bib27","series-title":"Metabolic Syndrome","first-page":"279","article-title":"Non-alcoholic steatohepatitis","author":"Ahmed","year":"2005"},{"key":"10.1016\/j.clbc.2016.12.004_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ajg.2011.01.003","article-title":"Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer","volume":"12","author":"Akhondi-Meybodi","year":"2011","journal-title":"Arab J Gastroenterol"},{"key":"10.1016\/j.clbc.2016.12.004_bib29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4254\/wjh.v7.i6.846","article-title":"Non-alcoholic fatty liver disease: the diagnosis and management","volume":"7","author":"Abd El-Kader","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clbc.2016.12.004_bib30","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clbc.2016.12.004_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cld.2015.10.008","article-title":"Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease","volume":"20","author":"Hannah","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clbc.2016.12.004_bib32","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1046\/j.1365-2036.2001.01083.x","article-title":"Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study","volume":"15","author":"Hasegawa","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clbc.2016.12.004_bib33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/jhep.2003.50316","article-title":"Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E","volume":"38","author":"Kugelmas","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.clbc.2016.12.004_bib34","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","article-title":"Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis","volume":"98","author":"Harrison","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clbc.2016.12.004_bib35","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1542-3565(04)00457-4","article-title":"A\u00a0pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis","volume":"2","author":"Sanyal","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clbc.2016.12.004_bib36","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0022-3476(00)05040-X","article-title":"Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study","volume":"136","author":"Lavine","year":"2000","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.clbc.2016.12.004_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alphaagonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clbc.2016.12.004_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clbc.2016.12.004_bib39","doi-asserted-by":"crossref","first-page":"12956","DOI":"10.3748\/wjg.v20.i36.12956","article-title":"Non-alcoholic fatty liver disease: what the clinician needs to know","volume":"20","author":"Machado","year":"2014","journal-title":"World J Gastroenterol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820916305699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820916305699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:29Z","timestamp":1761513329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820916305699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1526820916305699"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2016.12.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Relationship Between Tamoxifen-associated Nonalcoholic Fatty Liver Disease and the Prognosis of Patients With Early-stage Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}